Feb 25, 2026 04:07PM
Aug 26, 2025 07:12PM
Aug 25, 2025 08:03AM
Aug 25, 2025 08:03AM
Apr 8, 2025 08:07AM
Apr 8, 2025 08:06AM
Apr 8, 2025 08:06AM Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
Feb 26, 2025 04:13PM
Jan 21, 2025 08:20AM
Jan 21, 2025 08:19AM
Jan 8, 2025 03:06PM
Jan 8, 2025 03:04PM
Jan 8, 2025 12:31PM
Jan 8, 2025 12:30PM Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Nov 6, 2024 04:12PM
Sep 24, 2024 06:20AM
Sep 24, 2024 06:00AM
Sep 12, 2024 01:00AM
Aug 20, 2024 08:03AM
Aug 7, 2024 04:11PM
Jul 24, 2024 08:08AM Catalyst Pharmaceuticals (CPRX) Enters Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE in Canada
Jul 24, 2024 08:05AM
Jul 22, 2024 08:03AM
May 30, 2024 01:42PM
May 30, 2024 01:41PM
May 28, 2024 08:03AM
May 8, 2024 04:16PM
May 1, 2024 08:00AM Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
Apr 25, 2024 01:00AM
Apr 22, 2024 08:00AM
Mar 28, 2024 08:03AM
Mar 27, 2024 08:03AM
Mar 14, 2024 02:00AM
Mar 13, 2024 07:55AM
Mar 13, 2024 07:55AM Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Mar 5, 2024 08:03AM
Feb 28, 2024 06:03PM
Feb 27, 2024 08:03AM
Feb 27, 2024 08:03AM
Feb 21, 2024 09:00AM
Feb 21, 2024 09:00AM
Feb 14, 2024 08:03AM Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Jan 9, 2024 04:05PM
Jan 5, 2024 08:02AM
Jan 5, 2024 08:02AM
Jan 4, 2024 04:50PM
Jan 4, 2024 04:49PM
Dec 18, 2023 06:32AM
Dec 18, 2023 06:30AM Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
Dec 5, 2023 08:03AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All